Contact this trialFirst, we need to learn more about you.
Anti-tumor antibiotic, Anti-metabolites
CPX-351 + Quizartinib for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the side effects and best dose of CPX-351 in combination with quizartinib to treat acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351 contains chemotherapy drugs daunorubicin and cytarabine, which work in different ways to stop the growth of cancer cells. Quizartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The goal of this study is to learn if the combination of CPX-351 and quizartinib can help to control these diseases.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service